{'fraction_non_alphanumeric': 0.0281214848143982, 'fraction_numerical': 0.020247469066366704, 'mean_word_length': 6.416666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria

Aspirin hypersensitivity associated with chronic rhinosinusitis—with or without nasal polyposis—and asthma resistant to conventional therapy defines the aspirin‐exacerbated respiratory disease (AERD). We describe the case of a 15‐year‐old female patient with adverse reaction to aspirin, chronic rhinosinusitis, and severe asthma. She also experienced chronic idiopathic urticaria worsened by non‐steroidal anti‐inflammatory drug administration. AERD was diagnosed based on clinical history and symptoms. Given the poor responsiveness to standard therapy for respiratory and cutaneous symptoms, omalizumab was administered for 24 weeks with control of respiratory symptoms and short term improvement of cutaneous symptoms. Pediatr Pulmonol. 2017;52:E26–E28. © 2016 Wiley Periodicals, Inc.